Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



An Expanded Access Study of the Feasibility of Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients

Multiple Cancer Types

Hematologic, Leukemia, Lymphoma, Pediatric Leukemia, Pediatric Lymphoma, Pediatric Supportive Care, Pediatrics, Supportive Care
N/A
Kitko, Carrie
NCT01200017
VICCPED1619

Prospective Observational Trial of Low-Dose Skin Electron Therapy in Mycosis Fungoides Using Rotisserie Technique

Lymphoma

Lymphoma
N/A
Kirschner, Austin
NCT02702310
VICCRAD1633

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

Multiple Cancer Types

This randomized phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure compared to survivors who didn’t get any anthracycline chemotherapy. Heart failure happens when the heart muscle has been weakened and can’t pump blood as well as it should. Carvedilol may help lower the risk of cardiovascular complications.
Miscellaneous, Pediatrics
II
Friedman, Debra
NCT02717507
COGALTE1621

Immune Cells and Immune Factors from Healthy Donors or Transplant Recipients

Not Available
N/A
Engelhardt, Brian
VICCBMT1645

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

This phase II randomized trial studies how well high dose flu vaccine works in treating children who have undergone done stem cell transplant. Higher dose flu vaccine may build a better immune response and may provide better protection against the flu than the standard vaccine.
Not Available
II
Halasa, Natasha
NCT02860039
VICCPED1647

Natalizumab and Prednisone or Methylprednisolone in Treating Participants with High Risk Acute Graft-Versus-Host Disease

This phase II trial studies how well natalizumab and prednisone or methylprednisolone work in treating participants with high risk acute graft-versus-host disease. Graft-versus-host disease is caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Immunotherapy with monoclonal antibodies, such as natalizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Prednisone and methylprednisolone are steroids that helps suppress the immune system and reduce inflammation. It is not yet known how well natalizumab and prednisone or methylprednisolone work in treating participants with high risk acute graft-versus-host disease.
Not Available
II
Kitko, Carrie
NCT02133924
VICCPED1666

Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations

Lung

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.
Lung
II
Horn, Leora
NCT02864992
VICCTHO1691

AACR Project GENIE: Breast Cancer Sub-Project

Not Available
N/A
Park, Ben
VICCBRE1694

My Pathway: A Study Evaluating Herceptin / Perjeta, Tarceva, Zelboraf / Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Miscellaneous

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and / or are not suitable options per the treating physician's judgment.
Miscellaneous
II
Davis, Elizabeth
NCT02091141
VICCMD16103

Prospective Observational Trial of an Absorbable Hydrogel Spacer in Prostate Cancer Radiotherapy

Prostate

Prostate
N/A
Kirschner, Austin
VICCURO16112

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: